Sendur Suleyman Nahit, Baykal Gokhan, Firlatan Busra, Aydin Busra, Lay Incilay, Dagdelen Selcuk, Alikasifoglu Mehmet, Erbas Tomris
Department of Endocrinology and Metabolism, Hacettepe University School of Medicine, Ankara, Turkey.
Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey.
Horm Mol Biol Clin Investig. 2022 Jul 19;43(3):251-261. doi: 10.1515/hmbci-2022-0009. eCollection 2022 Sep 1.
Several metabolic disturbances are seen in acromegaly however, data regarding the contribution of irisin to these disturbances is currently insufficient. In a cohort of patients with acromegaly, we measured serum irisin levels in active and controlled cases and determined independent factors that effect serum irisin including fibronectin type III domain-containing protein 5 (FNDC5) genotyping.
A cross-sectional case-control study including 46 patients with acromegaly (28 F/18 M, age: 50.3 ± 12.1 year, BMI: 30.7 ± 5.1 kg/m) and 81 age-, gender-, body mass index- and body composition-matched healthy controls was conducted. 15 acromegalic patients (33%) had active disease. Irisin levels were measured by enzyme-linked immunosorbent assay. Three different regions (rs3480, rs1746661, and rs16835198) of FNDC5 were subjected to polymorphism analyses.
Both groups were overweight and had similar body composition. Irisin levels were lower in patients with acromegaly than controls (median [IQR]: 44.8 [41.7-46.7] ng/mL vs. 51.7 [45.5-60.1] ng/mL, p≤0.001, respectively). Active and controlled patients had similar irisin levels. Irisin was not correlated with growth hormone (GH), insulin-like growth factor 1 (IGF-1), and IGF-1 index. In multiple linear regression model, somatostatin receptor ligand use (=-20.30, 95% CI [-34]-[-6], p=0.006) was determined as the only independent factor that affect serum irisin.
Serum irisin levels are low in patients with acromegaly who are on somatostatin receptor ligand therapy. Single nucleotide polymorphisms (SNPs) of FNDC5 have no independent effects on circulating irisin levels under somatostatin ligand action. Endocrine muscle functions also seem to be regulated by somatostatin action, which requires further studies.
肢端肥大症患者存在多种代谢紊乱，但目前关于鸢尾素对这些紊乱的影响的数据尚不充分。在一组肢端肥大症患者中，我们测量了活动期和病情得到控制的患者的血清鸢尾素水平，并确定了影响血清鸢尾素的独立因素，包括含III型纤连蛋白结构域蛋白5（FNDC5）基因分型。
进行了一项横断面病例对照研究，纳入46例肢端肥大症患者（28例女性/18例男性，年龄：50.3±12.1岁，体重指数：30.7±5.1kg/m²）和81例年龄、性别、体重指数和身体成分匹配的健康对照。15例肢端肥大症患者（33%）患有活动期疾病。采用酶联免疫吸附测定法测量鸢尾素水平。对FNDC5的三个不同区域（rs3480、rs1746661和rs16835198）进行多态性分析。
两组均超重且身体成分相似。肢端肥大症患者的鸢尾素水平低于对照组（中位数[四分位间距]：44.8[41.7 - 46.7]ng/mL对51.7[45.5 - 60.1]ng/mL，p≤0.001）。活动期和病情得到控制的患者鸢尾素水平相似。鸢尾素与生长激素（GH）、胰岛素样生长因子1（IGF - 1）及IGF - 1指数均无相关性。在多元线性回归模型中，生长抑素受体配体的使用（β = - 20.30，95%置信区间[- 34]-[- 6]，p = 0.006）被确定为影响血清鸢尾素的唯一独立因素。
接受生长抑素受体配体治疗的肢端肥大症患者血清鸢尾素水平较低。在生长抑素配体作用下，FNDC5的单核苷酸多态性（SNP）对循环鸢尾素水平无独立影响。内分泌肌肉功能似乎也受生长抑素作用的调节，这需要进一步研究。
